BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells

FASEB Journal

Volumn 24, Issue 6, 2010, Pages 2040-2055

  Nehra, Ruchi ^a   Riggins, Rebecca B ^a   Shajahan, Ayesha N ^a   Zwart, Alan ^a   Crawford, Anatasha C ^a   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autophagy; Breast neoplasms; RELA; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; CASPASE 8; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P62;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL DEATH; CELL FATE; CELL FUNCTION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 8; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 77953488930     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-138305     Document Type: Article

References (52)

1. Clarke, R., Leonessa, F., Welch, J. N., and Skaar, T. C. (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53, 25-71 (Pubitemid 32173107)
2. Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., and Hilakivi-Clarke, L. A. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22, 7316-7339
3. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M. J. (2008) Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96
4. Riggins, R., Bouton, A. H., Liu, M. C., and Clarke, R. (2005) Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam. Horm. 71, 201-237
5. Encarnacion, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A., and Osborne, C. K. (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26, 237-246
6. Kuukasjarvi, T., Kononen, J., Helin, H., Holli, K., and Isola, J. (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol. 14, 2584-2589 (Pubitemid 26300127)
7. Bachleitner-Hofmann, T., Pichler-Gebhard, B., Rudas, M., Gnant, M., Taucher, S., Kandioler, D., Janschek, E., Dubsky, P., Roka, S., Sporn, E., and Jakesz, R. (2002) Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin. Cancer Res. 8, 3427-3432 (Pubitemid 35340717)
8. Kuske, B., Naughton, C., Moore, K., Macleod, K. G., Miller, W. R., Clarke, R., Langdon, S. P., and Cameron, D. A. (2006) Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr. Relat. Cancer 13, 1121-1133
9. Clarke, R., Shajahan, A. N., Riggins, R., Cho, Y., Crawford, A. C., Xuan, J., Wang, Y., Zwart, A., Nehra, N., and Liu, M. C. (2009) Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J. Steroid. Biochem. Mol. Biol. 114, 8-20
10. Brunner, N., Boulay, V., Fojo, A., Freter, C. E., Lippman, M. E., and Clarke, R. (1993) Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 53, 283-290 (Pubitemid 23031838)
11. Brunner, N., Boysen, B., Jirus, S., Skaar, T., Holst-Hansen, C., Lippman, J., Frandsen, T., Spang-Thomsen, M., Fuqua, S. A. W., and Clarke, R. (1997) MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 57, 3486-3493 (Pubitemid 27355496)
12. Gu, Z., Lee, R. Y., Skaar, T. C., Bouker, K. B., Welch, J. N., Lu, J., Liu, A., Zhu, Y., Davis, N., Leonessa, F., Brunner, N., Wang, Y., and Clarke, R. (2002) Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780). Cancer Res. 62, 3428-3437 (Pubitemid 34651389)
13. Baldwin, A. S. (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107, 241-246
14. Kim, D. W., Sovak, M. A., Zanieski, G., Nonet, G., Romieu-Mourez, R., Lau, A. W., Hafer, L. J., Yaswen, P., Stampfer, M., Rogers, A. E., Russo, J., and Sonenshein, G. E. (2000) Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21, 871-879 (Pubitemid 30265128)
15. Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., and Sonenshein, G. E. (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952-2960 (Pubitemid 28022831)
16. Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K., and Baldwin, A. S., Jr. (2000) Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19, 1123-1131
17. Pratt, M. A. C., Bishop, T. E., White, D., Yasvinski, G., Menard, M., Niu, M. Y., and Clarke, R. (2003) Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol. Cell. Biol. 23, 6887-6900
18. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., and Sledge, G. W. (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17, 3629-3639 (Pubitemid 27281838)
19. Shishodia, S., and Aggarwal, B. B. (2004) Nuclear factor-kappaB: a friend or a foe in cancer? Biochem. Pharmacol. 68, 1071-1080
20. Verma, I. M. (2004) Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann Rheum. Dis. 63(Suppl. 2), ii57-ii61
21. Hehner, S. P., Heinrich, M., Bork, P. M., Vogt, M., Ratter, F., Lehmann, V., Schulze-Osthoff, K., Droge, W., and Schmitz, M. L. (1998) Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J. Biol. Chem. 273, 1288-1297
22. Curry, E. A., III, Murry, D. J., Yoder, C., Fife, K., Armstrong, V., Nakshatri, H., O'Connell, M., and Sweeney, C. J. (2004) Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest. New Drugs 22, 299-305
23. Wen, J., You, K. R., Lee, S. Y., Song, C. H., and Kim, D. G. (2002) Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem. 277, 38954-38964
24. Nakshatri, H., Rice, S. E., and Bhat-Nakshatri, P. (2004) Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23, 7330-7344
25. Riggins, R., Zwart, A., Nehra, R., Agarwal, P., and Clarke, R. (2005) The NFκB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen resistant breast cancer cells. Mol. Cancer Ther. 4, 33-41 (Pubitemid 40268064)
26. Bouker, K. B., Skaar, T. C., Fernandez, D. R., O'Brien, K. A., and Clarke, R. (2004) Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, fulvestrant). Cancer Res. 64, 4030-4039
27. Drew, P. D., Franzoso, G., Becker, K. G., Bours, V., Carlson, L. M., Siebenlist, U., and Ozato, K. (1995) NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. J. Interferon. Cytokine Res. 15, 1037-1045 (Pubitemid 26006282)
28. Zhou, Y., Yau, C., Gray, J. W., Chew, K., Dairkee, S. H., Moore, D. H., Eppenberger, U., Eppenberger-Castori, S., and Benz, C. C. (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7, 59
29. Brünner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E., and Clarke, R. (1993) MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53, 3229-3232 (Pubitemid 23223286)
30. Howell, A., DeFriend, D., Robertson, J. F. R., Blamey, R. W., and Walton, P. (1995) Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345, 29-30
31. Butler, W. B., and Fontana, J. A. (1992) Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7. Cancer Res. 52, 6164-6167
32. Vindelov, L. L., Christensen, I. J., and Nissen, N. I. (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3, 323-327 (Pubitemid 13087609)
33. Romanelli, S., Perego, P., Pratesi, G., Carenini, N., Tortoreto, M., Zunino, F. (1998) In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother. Pharmacol. 41, 385-390
34. Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Jr., Sledge, G. W., Jr., and Nakshatri, H. (2000) Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19, 4159-4169
35. Klionsky, D. J., and others (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4, 151-175
36. Lilling, G., Hacohen, H., Nordenberg, J., Livnat, T., Rotter, V., and Sidi, Y. (2000) Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio? Cancer Lett. 161, 27-34
37. Teixeira, C., Reed, J. C., and Pratt, M. A. (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55, 3902-3907
38. Viatour, P., Bentires-Alj, M., Chariot, A., Deregowski, V., de Leval, L., Merville, M. P., and Bours, V. (2003) NF- kappa B2/p100 induces Bcl-2 expression. Leukemia 17, 1349-1356
39. Taylor, I. W., Hodson, P. J., Green, M. D., and Sutherland, R. L. (1983) Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res. 43, 4007-4010 (Pubitemid 13041019)
40. Samaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M., Smith, M. J., Browning, D., Rawson, J., Smith, S. B., Barrett, J. T., and Schoenlein, P. V. (2008) A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol. Cancer Ther. 7, 2977-2987
41. Komatsu, M., Waguri, S., Koike, M., Sou, Y. S., Ueno, T., Hara, T., Mizushima, N., Iwata, J., Ezaki, J., Murata, S., Hamazaki, J., Nishito, Y., Iemura, S., Natsume, T., Yanagawa, T., Uwayama, J., Warabi, E., Yoshida, H., Ishii, T., Kobayashi, A., Yamamoto, M., Yue, Z., Uchiyama, Y., Kominami, E., and Tanaka, K. (2007) Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131, 1149-1163
42. Narita, M., Shimizu, S., Ito, T., Chittenden, T., Lutz, R. J., Matsuda, H., and Tsujimoto, Y. (1998) Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc. Natl. Acad. Sci. U. S. A. 95, 14681-14686
43. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490 (Pubitemid 28391864)
44. Basanez, G., Nechushtan, A., Drozhinin, O., Chanturiya, A., Choe, E., Tutt, S., Wood, K. A., Hsu, Y., Zimmerberg, J., and Youle, R. J. (1999) Bax, but not Bcl-xL, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc. Natl. Acad. Sci. U. S. A. 96, 5492-5497
45. Crawford, A. C., Riggins, R. B., Shajahan, A. N., Zwart, A., and Clarke, R. (2010) Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS ONE 5, e8604
46. Reed, J. C. (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7, 541-546
47. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (Pubitemid 28391865)
48. Eskes, R., Desagher, S., Antonsson, B., and Martinou, J. C. (2000) Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell. Biol. 20, 929-935
49. Desagher, S., and Martinou, J. C. (2000) Mitochondria as the central control point of apoptosis. Trends Cell Biol. 10, 369-377
50. Goonesinghe, A., Mundy, E. S., Smith, M., Khosravi-Far, R., Martinou, J. C., and Esposti, M. D. (2005) Pro-apoptotic Bid induces membrane perturbation by inserting selected lysolipids into the bilayer. Biochem. J. 387, 109-118
51. Kim, H., Chung, H., Kim, H. J., Lee, J. Y., Oh, M. Y., Kim, Y., and Kong, G. (2008) Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 112, 287-296
52. Kawauchi, K., Araki, K., Tobiume, K., and Tanaka, N. (2008) p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 10, 611-618